Highlights

  • Nexsen Limited shares surged 9.09% to AUD 0.18 on 31 March 2026, following the announcement of a strategic government grant.
  • The Company’s subsidiary was awarded a HK$6 million (approx. AUD 1.2 million) non-dilutive IGNITE Grant from the Hong Kong Science and Technology Parks Corporation (HKSTP).
  • Funds will be directed toward clinical validation and establishing a manufacturing and distribution hub in Hong Kong for StrepSure.
  • The initiative targets the massive Asia-Pacific market, which sees approximately 47 million annual births.
  • Total non-dilutive grant support for Nexsen's programs now exceeds AUD 13 million.

Nexsen Limited (ASX:NXN) shares advanced 9.09% to AUD 0.18 during the afternoon session on 31 March 2026. The upward movement follows the announcement that the Company has secured a HK$6 million (approximately AUD 1.2 million) IGNITE Grant to fund its expansion into the Asia-Pacific region.

While the stock remains down 35.71% over the past year, today's rally reflects investor approval of the Company's ability to fund key commercial milestones through non-dilutive capital.

Strengthening the Asia-Pacific Execution Strategy

The IGNITE Grant, awarded by the Hong Kong Science and Technology Parks Corporation (HKSTP), serves as a critical financial catalyst for Nexsen’s wholly owned subsidiary, Nexsen Hong Kong Limited. The capital is specifically earmarked for the regional development and optimization of StrepSure, the Company’s rapid point-of-care diagnostic test for Group B Streptococcus (GBS).

Nexsen plans to utilize the funding to:

  • Commence Clinical Validation: Leveraging established Hong Kong hospital networks to generate real-world performance data.
  • Scale Manufacturing: Establishing a local manufacturing and distribution hub to complement existing Australian capacity.
  • Product Optimization: Tailoring the StrepSure device design to meet specific clinical workflows and regulatory requirements within the Asian healthcare landscape.

Hong Kong as a Strategic Launchpad

Management has identified Hong Kong as a high-priority base due to its robust clinical infrastructure and favorable regulatory environment. The region operates under the Medical Device Administrative Control System (MDACS), which offers a streamlined pathway for in vitro diagnostics (IVD) based on local clinical validation and recognized quality standards.

By establishing a permanent footprint in Hong Kong, Nexsen aims to tap into a significant addressable market. The broader Asia-Pacific region accounts for more than 33 million births annually, and with a GBS prevalence rate of approximately 21.5%, the demand for rapid, accurate point-of-care testing is substantial. The Hong Kong hub will allow for faster product iteration and reliable supply chains to meet this regional demand.

Capital Efficiency and Global Rollout

A core theme of the update is Nexsen’s commitment to capital-efficient growth. By securing non-dilutive funding, the Company avoids shareholder dilution while advancing toward commercial readiness. To date, Nexsen has successfully attracted over AUD 13 million in cumulative grant support across its diagnostic programs, which also include rapid kidney function tests for Acute Kidney Injury and Chronic Kidney Disease.

The Hong Kong manufacturing capability is intended to eventually support large-scale production, building upon the Company's Australian facility which currently has the capacity to produce up to 1 million devices per year.

Investor Takeaway

The award of the IGNITE Grant is a clear validation of Nexsen’s (ASX:NXN) technical strategy by a major international governmental body. For investors, the significance lies in the de-risking of the Asia-Pacific expansion. By securing a clear regulatory pathway and funding for local clinical trials, Nexsen has removed major hurdles toward entering a market with 47 million annual births. If the local validation studies reflect the high accuracy of previous StrepSure data, the Company will be well-positioned to transition from a development-stage entity to a commercial-scale diagnostic leader in one of the world's most populous regions.